इम्यूनोलॉजिकल तकनीक और संक्रामक रोगों का जर्नल

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

Subhajit Dasgupta and Mausumi Bandyopadhyay

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.

अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।

विज्ञान प्रौद्योगिकी का अन्वेषण करें

जर्नल हाइलाइट्स